How did ADGM's revenue and expenses shift in Q4 2024?

ADGM's revenue and expenses in Q4 2024 showed notable shifts, reflecting changes in business dynamics and operational focus:

1. **Revenue by Business**: Concentra's revenue for Q4 2024 was $465.0 million, marking a 5.5% increase from $440.7 million in the same quarter of the previous year. This growth was driven by expanded operations and the integration of recently acquired Nova Medical Centers.
2. **Net Income and Earnings Per Share**: The company reported a net income of $22.8 million and earnings per share (EPS) of $0.17 for Q4 2024, compared to $2.8 million and EPS of $0.15 in Q4 2023. This indicates a significant improvement in profitability.
3. **Adjusted EBITDA**: Concentra's Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q4 2024 was $77.5 million, representing a 13.6% increase from $68.3 million in Q4 2023. This suggests enhanced operational efficiency and cash flow generation.
4. **Cash Balance and Leverage**: The company ended the quarter with a cash balance of $183.3 million and a net leverage ratio of 3.46x. This financial stability supports ongoing strategic initiatives and future growth opportunities.

In summary, ADGM's Q4 2024 financials reflect robust growth, improved profitability, and enhanced operational efficiency, positioning the company well for continued performance in 2025.